Show Navigation

Search Results

Refine Search
Match all words
Match any word
Prints
Personal Use
Royalty-Free
Rights-Managed
(leave unchecked to
search all images)
{ 45 images found }

Loading ()...

  • Baltimore, Maryland - May 06, 2021: The Center for Psychedelic and Consciousness Research is located inside the Joseph V. Brady Behavioral Biology Research Building, at Johns Hopkins Bayview Medical Center in Baltimore. The center’s work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_190.jpg
  • Baltimore, Maryland - May 06, 2021: The Center for Psychedelic and Consciousness Research is located inside the Joseph V. Brady Behavioral Biology Research Building, at Johns Hopkins Bayview Medical Center in Baltimore. The center’s work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_192.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_166.jpg
  • Baltimore, Maryland - May 06, 2021: Paul Stamets, a prominent mushroom expert and protagonist of the film “Fantastic Fungi” drew this picture of a mushroom for Dr. Roland Griffiths which hangs in his office at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_082.jpg
  • Baltimore, Maryland - May 06, 2021: The Center for Psychedelic and Consciousness Research is located inside the Joseph V. Brady Behavioral Biology Research Building, at Johns Hopkins Bayview Medical Center in Baltimore. The center’s work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_194.jpg
  • Baltimore, Maryland - May 06, 2021: One of the therapy rooms at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_185.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_154.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards is photographed at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center’s work uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_121.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards is photographed at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center’s work uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_103.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards is photographed at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center’s work uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_099.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards is photographed at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center’s work uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_098.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards, left, and Dr. Roland R. Griffiths, right, in the front office area of the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_065.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed at the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_035.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards and Dr. Roland R. Griffiths sit on one of their plush couches at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_028.jpg
  • Baltimore, Maryland - May 06, 2021: A dose of psilocybin sits in a ceremonial chalice called a copal burner, “but we use it to dispense the capsule,” said Dr. Roland Griffiths director of Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_105.jpg
  • Baltimore, Maryland - May 06, 2021: A colorful painting and an empty desk chair sit in the lobby of the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. COVID-19-related quarantining and work-from-home orders has slowed their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism — which has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_053.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_160.jpg
  • Baltimore, Maryland - May 06, 2021: A headphone system, a blood pressure monitor, first aid kit, and a tissue box sit in one of the therapy rooms at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_129.jpg
  • Baltimore, Maryland - May 06, 2021: A wood carving and a painting of mushrooms that contain psilocybin decorate Dr. Roland Griffiths’s office at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_081.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards and Dr. Roland R. Griffiths sit on one of their plush couches at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_047.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards and Dr. Roland R. Griffiths sit on one of their plush couches at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_018.jpg
  • Baltimore, Maryland - May 06, 2021: A stone mushroom sculpture peeks from behind a plush couch in one of the therapy rooms at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_180.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_170.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_150.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_149.jpg
  • Baltimore, Maryland - May 06, 2021: A dose of psilocybin sits in a ceremonial chalice called a copal burner, “but we use it to dispense the capsule,” said Dr. Roland Griffiths director of Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_104.jpg
  • Baltimore, Maryland - May 06, 2021: A wood carving of a mushroom that contains psilocybin in Dr. Roland Griffiths’s office at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_077.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards, left, and Dr. Roland R. Griffiths, right, in the front office area of the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_068.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards and Dr. Roland R. Griffiths sit on one of their plush couches at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_044.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards and Dr. Roland R. Griffiths sit on one of their plush couches at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_025.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards is photographed at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. The center’s work uses psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_118.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards, left, and Dr. Roland R. Griffiths, right, in the front office area of the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_060.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards and Dr. Roland R. Griffiths sit on one of their plush couches at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_021.jpg
  • Baltimore, Maryland - May 06, 2021: Headphones, a blood pressure monitor, and a tissue box sit next to the plush couch in one of the therapy rooms at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_096.jpg
  • Baltimore, Maryland - May 06, 2021: Filing cabinets detailing Dr. Roland Griffiths’s subject matter line his office at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_078.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards, left, and Dr. Roland R. Griffiths, right, in the front office area of the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_062.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards and Dr. Roland R. Griffiths sit on one of their plush couches at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_045.jpg
  • Baltimore, Maryland - May 06, 2021: A leather chair used by the therapists inside a therapy room at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_174.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards, left, and Dr. Roland R. Griffiths, right, in the front office area of the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_061.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. William Richards and Dr. Roland R. Griffiths sit on one of their plush couches at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021. Their work using psilocybin and controlled therapy sessions with patients who suffer from major depression, anorexia, depression associated with Alzheimer’s, nicotine addiction, and depression associated with alcoholism, has shown effectiveness. <br />
<br />
CREDIT: Matt Roth for The New York Times<br />
Assignment ID:
    210506_Medical_Psychedelics_046.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021.
    210506_Medical_Psychedelics_141.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021.
    210506_Medical_Psychedelics_134.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021.
    210506_Medical_Psychedelics_145.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021.
    210506_Medical_Psychedelics_148.jpg
  • Baltimore, Maryland - May 06, 2021: Dr. Roland R. Griffiths, Director of the Center for Psychedelic and Consciousness Research is photographed in the center’s offices at the Johns Hopkins Bayview Medical Center in Baltimore Thursday May 6, 2021.
    210506_Medical_Psychedelics_133.jpg
  • Facebook
  • Twitter
x

Matt Roth Baltimore Photographer Editorial & Commercial

  • Portfolio
  • About
  • Contact
  • Archive
    • All Galleries
    • Search
    • Cart
    • Lightbox
    • Client Area
  • Instagram
  • tumblr